Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection

PLoS Pathog. 2013;9(10):e1003658. doi: 10.1371/journal.ppat.1003658. Epub 2013 Oct 10.

Abstract

The role of Type I interferon (IFN) during pathogenic HIV and SIV infections remains unclear, with conflicting observations suggesting protective versus immunopathological effects. We therefore examined the effect of IFNα/β on T cell death and viremia in HIV infection. Ex vivo analysis of eight pro- and anti-apoptotic molecules in chronic HIV-1 infection revealed that pro-apoptotic Bak was increased in CD4+ T cells and correlated directly with sensitivity to CD95/Fas-mediated apoptosis and inversely with CD4+ T cell counts. Apoptosis sensitivity and Bak expression were primarily increased in effector memory T cells. Knockdown of Bak by RNA interference inhibited CD95/Fas-induced death of T cells from HIV-1-infected individuals. In HIV-1-infected patients, IFNα-stimulated gene expression correlated positively with ex vivo T cell Bak levels, CD95/Fas-mediated apoptosis and viremia and negatively with CD4+ T cell counts. In vitro IFNα/β stimulation enhanced Bak expression, CD95/Fas expression and CD95/Fas-mediated apoptosis in healthy donor T cells and induced death of HIV-specific CD8+ T cells from HIV-1-infected patients. HIV-1 in vitro sensitized T cells to CD95/Fas-induced apoptosis and this was Toll-like receptor (TLR)7/9- and Type I IFN-dependent. This sensitization by HIV-1 was due to an indirect effect on T cells, as it occurred in peripheral blood mononuclear cell cultures but not purified CD4+ T cells. Finally, peak IFNα levels and viral loads correlated negatively during acute SIV infection suggesting a potential antiviral effect, but positively during chronic SIV infection indicating that either the virus drives IFNα production or IFNα may facilitate loss of viral control. The above findings indicate stage-specific opposing effects of Type I IFNs during HIV-1 infection and suggest a novel mechanism by which these cytokines contribute to T cell depletion, dysregulation of cellular immunity and disease progression.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Apoptosis / immunology*
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / metabolism
  • CD8-Positive T-Lymphocytes / pathology
  • Child
  • Child, Preschool
  • Female
  • HIV Infections / immunology*
  • HIV Infections / metabolism
  • HIV Infections / pathology
  • HIV-1 / immunology*
  • HIV-1 / metabolism
  • Humans
  • Immunity, Cellular
  • Infant
  • Interferon-alpha / immunology*
  • Interferon-alpha / metabolism
  • Interferon-beta / immunology*
  • Interferon-beta / metabolism
  • Macaca mulatta
  • Male
  • Toll-Like Receptor 7 / immunology
  • Toll-Like Receptor 7 / metabolism
  • Toll-Like Receptor 9 / immunology
  • Toll-Like Receptor 9 / metabolism
  • Up-Regulation / immunology*
  • Viral Load / immunology
  • Viremia / immunology
  • Viremia / metabolism
  • bcl-2 Homologous Antagonist-Killer Protein / biosynthesis
  • bcl-2 Homologous Antagonist-Killer Protein / immunology*
  • fas Receptor / immunology
  • fas Receptor / metabolism

Substances

  • BAK1 protein, human
  • FAS protein, human
  • Interferon-alpha
  • TLR7 protein, human
  • TLR9 protein, human
  • Toll-Like Receptor 7
  • Toll-Like Receptor 9
  • bcl-2 Homologous Antagonist-Killer Protein
  • fas Receptor
  • Interferon-beta